ArticleNeuro-oncology2022
Consensus core clinical data elements for meningiomas (v2021.1).
Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The concept, intention, and evaluation of the term treatment-refractory meningioma.Journal of neuro-oncology · 2025Pooled it
- Assessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology.Neuro-oncology · 2026Article
- Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective study.Neuro-oncology · 2025Article
- Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma.Nature medicine · 2024Article
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- A semi-automatic segmentation method for meningioma developed using a variational approach model.The neuroradiology journal · 2024Article
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Outcomes and predictors of response to fractionated radiotherapy as primary treatment for intracranial meningiomas.Clinical and translational radiation oncology · 2023Article
- Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.Acta neuropathologica · 2023Article
- Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories.Brain pathology (Zurich, Switzerland) · 2023Article
- Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study.Journal of neuro-oncology · 2023Article
- Development and implementation of the National Heart, Lung, and Blood Institute COVID-19 common data elements.Journal of clinical and translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundWith increasing molecular analyses of meningiomas, there is a need to harmonize language used to capture clinical data across centers to ensure that molecular alterations are appropriately linked to clinical variables of interest. Here the International Consortium on Meningiomas presents a set of core and supplemental meningioma-specific common data elements (CDEs) to facilitate comparative and pooled analyses.
methodsThe generation of CDEs followed the 4-phase process similar to other National Institute of Neurological Disorders and Stroke (NINDS) CDE projects: discovery, internal validation, external validation, and distribution.
resultsThe CDEs were organized into patient- and tumor-level modules. In total, 17 core CDEs (10 patient level and 7 tumor level) as well as 14 supplemental CDEs (7 patient level and 7 tumor level) were defined and described. These CDEs are now made publicly available for dissemination and adoption.
conclusionsCDEs provide a framework for discussion in the neuro-oncology community that will facilitate data-sharing for collaborative research projects and aid in developing a common language for comparative and pooled analyses. The meningioma-specific CDEs presented here are intended to be dynamic parameters that evolve with time and The Consortium welcomes international feedback for further refinement and implementation of these CDEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.